NeRRe’s ambition is to unlock the significant potential of its full pipeline in particular to progress the two lead NK antagonists to the next stage of development. The NeRRe focus is on developing novel treatments to address common, chronic and debilitating conditions that affect millions of people around the world on a daily basis.
NK-1 antagonism: There is a strong pre-clinical and clinical rationale for the role of NK-1 antagonists in the treatment of chronic conditions triggered by neuronal hypersensitivity. NeRRe is actively developing its late stage NK-1 antagonist orvepitant for a common, chronic and debilitating respiratory condition for which there is no currently approved treatment.
Dual mechanism NK-1,3 antagonism: Novel emerging science points to the role of the NK-3 (and -1) receptor system in a range of Women‘s Heath indications, by virtue of the modulatory role it plays on the centrally located “KNDy” (kisspeptin-neurokinin B-dynorphin) neurone network. This complex has a controlling influence on 2 major pathways: the heat dissipating Thermoregulatory centre; and the Hypothalamic-Pituitary-Gonadotrophin (HPG) axis which regulates sex hormone release. NeRRe is actively exploring the role of its dual mechanism NK-1,3 antagonist NT-814 as a treatment for debilitating post-menopausal vasomotor symptoms.